Home Newsfeeds Hillstream BioPharma Regained Compliance With Nasdaq Listing Minimum Bid Price Rule

Hillstream BioPharma Regained Compliance With Nasdaq Listing Minimum Bid Price Rule

Hillstream BioPharma, Inc. (NASDAQ: HILS) today announced that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.

byCharles Gross

February 15, 2023

1 minute read

Hillstream BioPharma, Inc. (NASDAQ:HILS) today announced that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.

Hot
News

Media Report On UAE Considering Leaving OPEC Is “Far From The Truth”

By Happy Mohamed

March 3, 10:49 AM

- Reuters, Citing Source With Direct Knowledge Of The Matter

USO

Radius Global Infr Q2 EPS $(0.20) Up From $(0.50) YoY, Sales $32.57M Miss $34.09M Estimate

By Benzinga Newsdesk

August 8, 5:54 PM

Radius Global Infr (NASDAQ:RADI) reported quarterly losses of $(0.20) per share. This is a 60 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of

RADI

A Look Into Imperial Oil’s Debt

By Benzinga Insights

June 20, 11:00 AM

Shares of Imperial Oil Inc. (AMEX:IMO) increased by 4.47% in the past three months. When understanding a companies…

IMO

Catalyst Pharmaceuticals, Inc. Announces Pricing Of $150M Public Offering Of 10M Shares Of Common Stock At A Price Of $15/Share

By Benzinga Newsdesk

January 5, 9:09 AM

Catalyst Pharmaceuticals, Inc. ("Catalyst" or the "Company") (NASDAQ:CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per

CPRX

Hillstream BioPharma Regained Compliance With Nasdaq Listing Minimum Bid Price Rule

Related Posts

Media Report On UAE Considering Leaving OPEC Is “Far From The Truth”

Radius Global Infr Q2 EPS $(0.20) Up From $(0.50) YoY, Sales $32.57M Miss $34.09M Estimate

A Look Into Imperial Oil’s Debt

Catalyst Pharmaceuticals, Inc. Announces Pricing Of $150M Public Offering Of 10M Shares Of Common Stock At A Price Of $15/Share